December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Choroidal Blood Flow in Verteporfin Treatment of Age Related Macular Degeneration
Author Affiliations & Notes
  • JC Chen
    Department of Ophthalmology McGill University Montreal Retina & Laser Institute Montreal PQ Canada
  • JA Marinier
    School of Optometry University of Montreal Montreal PQ Canada
  • H Kergoat
    School of Optometry University of Montreal Montreal PQ Canada
  • JV Lovasik
    School of Optometry University of Montreal Montreal PQ Canada
  • MG Quigley
    Department of Ophthalmology McGill University Montreal Retina & Laser Institute Montreal PQ Canada
  • Footnotes
    Commercial Relationships   J.C. Chen, None; J.A. Marinier, None; H. Kergoat, None; J.V. Lovasik, None; M.G. Quigley, None. Grant Identification: NSERC, FRSQ, COETF
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 586. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JC Chen, JA Marinier, H Kergoat, JV Lovasik, MG Quigley; Choroidal Blood Flow in Verteporfin Treatment of Age Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2002;43(13):586.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:The clinical goal of Photodynamic Therapy (PDT) is to retard or arrest the deterioration of vision in exudative age related macular degeneration (ARMD). It involves an injection of a light-sensitive dye (e.g. verteporfin) which targets the aberrant neovascular membrane (NVM). When the dye-NVM complex is briefly exposed to a 689 nm light beam, the aberrant vessels are preferentially coagulated for the purpose of improving or stabilizing vision. This procedure is repeated every 3-4 months because leaky sub-retinal vessels are reformed. The purpose of the present study was to determine whether PDT has some yet unknown effects on the choroidal blood flow (ChBF). Here we looked for effects on the pulsatile ocular blood flow (POBF) originating from the choroid because with each treatment, some vaso-active substance may be released to alter normal ChBF. Methods:Fourteen adults (mean age: 76.5 ± 6.1 yrs) with wet ARMD and a NVM volunteered for this study. The POBF was measured twice with a UK OBF tonometer about 10 minutes before and after PDT. The choroidal pulse amplitude (PA) was also analyzed to derive some index of any changes in blood flow facility. Subjects remained seated during all testing. Results:For this cohort of subjects a paired t-test indicated that both the POBF and the PA measured before (POBF: 705.5 ± 57.5 µl/min; PA: 2.23 ± 0.21 mmHg) and after (731.6 ± 62.3 µl/min; PA: 2.27 ± 0.17 mmHg) PDT did not differ statistically (p≷0.05). No adverse effects were manifest during treatment and testing. Conclusion:Our data indicated that the global ChBF remained undisturbed shortly after PDT treatment targeted at aberrant sub-foveal vessels. This observation was clinically reassuring for continuing treatments of ARMD by PDT. Further studies are needed to evaluate the predictive value of POBF for long-term outcomes in ARMD management.

Keywords: 308 age-related macular degeneration • 516 photodynamic therapy • 346 choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×